CF PharmTech repurchases 32,000 H shares, treasury stock climbs to 0.28 % of authorised mandate

Bulletin Express05-20 18:43

CF PharmTech, Inc. disclosed that on 20 May 2026 it repurchased 32,000 H shares on the Hong Kong Stock Exchange, representing 0.0106 % of the company’s issued share capital (excluding treasury shares) prior to the transaction.

The shares were bought back at prices ranging from HKD 20.00 to HKD 20.52, translating to a volume-weighted average of HKD 20.2153 and an aggregate consideration of HKD 0.65 million. All repurchased shares are being held as treasury shares.

Following the transaction, outstanding shares (excluding treasury shares) declined to 301.37 million, while the treasury-share balance increased to 851,500. Total issued shares, including treasury stock, remained unchanged at 302.22 million.

The repurchases form part of the mandate approved on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. To date, 851,500 shares—or 0.28 % of the authorised limit—have been repurchased under this mandate. In accordance with Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or selling treasury shares until 19 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139643932?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 18:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139643932","market":"us","top_or_hot":-1,"title":"CF PharmTech repurchases 32,000 H shares, treasury stock climbs to 0.28 % of authorised mandate","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. disclosed that on 20 May 2026 it repurchased 32,000 H shares on the Hong Kong Stock Exchange, representing 0.0106 % of the company’s issued share capital (excluding treasury shares) prior to the transaction.</p>\n<p>The shares were bought back at prices ranging from HKD 20.00 to HKD 20.52, translating to a volume-weighted average of HKD 20.2153 and an aggregate consideration of HKD 0.65 million. All repurchased shares are being held as treasury shares.</p>\n<p>Following the transaction, outstanding shares (excluding treasury shares) declined to 301.37 million, while the treasury-share balance increased to 851,500. Total issued shares, including treasury stock, remained unchanged at 302.22 million.</p>\n<p>The repurchases form part of the mandate approved on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. To date, 851,500 shares—or 0.28 % of the authorised limit—have been repurchased under this mandate. In accordance with Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or selling treasury shares until 19 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech repurchases 32,000 H shares, treasury stock climbs to 0.28 % of authorised mandate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech repurchases 32,000 H shares, treasury stock climbs to 0.28 % of authorised mandate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-20 18:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. disclosed that on 20 May 2026 it repurchased 32,000 H shares on the Hong Kong Stock Exchange, representing 0.0106 % of the company’s issued share capital (excluding treasury shares) prior to the transaction.</p>\n<p>The shares were bought back at prices ranging from HKD 20.00 to HKD 20.52, translating to a volume-weighted average of HKD 20.2153 and an aggregate consideration of HKD 0.65 million. All repurchased shares are being held as treasury shares.</p>\n<p>Following the transaction, outstanding shares (excluding treasury shares) declined to 301.37 million, while the treasury-share balance increased to 851,500. Total issued shares, including treasury stock, remained unchanged at 302.22 million.</p>\n<p>The repurchases form part of the mandate approved on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. To date, 851,500 shares—or 0.28 % of the authorised limit—have been repurchased under this mandate. In accordance with Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or selling treasury shares until 19 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1139643932","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139643932","pubTimestamp":1779273820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. disclosed that on 20 May 2026 it repurchased 32,000 H shares on the Hong Kong Stock Exchange, representing 0.0106 % of the company’s issued share capital (excluding treasury...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech回购32,000股H股库存股升至授权授权的0.28%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. disclosed that on 20 May 2026 it repurchased 32,000 H shares on the Hong Kong Stock Exchange, representing 0.0106 % of the company’s issued share capital (excluding treasury shares) prior to the transaction.\nThe shares were bought back at prices ranging from HKD 20.00 to HKD 20.52, translating to a volume-weighted average of HKD 20.2153 and an aggregate consideration of HKD 0.65 million. All repurchased shares are being held as treasury shares.\nFollowing the transaction, outstanding shares (excluding treasury shares) declined to 301.37 million, while the treasury-share balance increased to 851,500. Total issued shares, including treasury stock, remained unchanged at 302.22 million.\nThe repurchases form part of the mandate approved on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. To date, 851,500 shares—or 0.28 % of the authorised limit—have been repurchased under this mandate. In accordance with Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or selling treasury shares until 19 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139643932","isCrawlerRequest":true}